FDA-Drug2026-04-15Class IIPROCESSING DEFECT
Fagron norepinephrine injection recalled for sterility concerns and port defect
Nationwide distributionDrugs
What this means
Fagron Compounding Services is recalling norepinephrine bitartrate injection due to two issues: the sterility of the product cannot be assured, and a blue plastic part on the administration port may detach during use. This medication is used in hospitals and medical facilities to treat critical conditions. Six specific lots distributed nationwide are affected.
- If you work in a hospital or medical facility, check if you have any of the affected lots (C274-000050004, C274-000050295, C274-000050773, C274-000051219, C274-000051318, or C274-000051602)
- Do not use any affected bags; remove them from stock immediately
- Contact Fagron Compounding Services or your supplier for instructions on return or disposal
- Notify your pharmacy or medical director if you have already used any affected doses
The agency's original wording
Hazard
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the U.S.A.
Affected count
5140 bags
Manufactured in
8710 E 34th St N, Wichita, KS, United States
Products
norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5027-02
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0439-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.